Pacira Pharmaceuticals Stock
Price
Target price
€14.10
€14.10
2.170%
0.3
2.170%
€40.02
03.10.24 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
There is an upward development for Pacira Pharmaceuticals compared to yesterday, with an increase of €0.30 (2.170%).
With 22 Buy predictions and 1 Sell predictions Pacira Pharmaceuticals is one of the favorites of our community.
With a target price of 40 € there is potential for a 183.69% increase which would mean more than doubling the current price of 14.1 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 2.170% | 10.400% | 0.730% | -50.360% | -53.691% | -71.369% | -58.434% |
| Rockwell Medical Inc. | -1.810% | -3.434% | 25.923% | 67.853% | 84.890% | -38.924% | -86.871% |
| Gritstone Oncology Inc | -4.230% | -64.075% | -53.680% | -89.963% | -89.704% | -97.955% | -97.532% |
| Avid Bioservices Inc | -4.100% | -2.010% | 12.069% | 11.429% | 59.836% | -46.133% | 106.568% |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Jefferies Financial Group Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock, down previously from $45.00.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Raymond James from $41.00 to $37.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat